# Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.

> **NCT02170987** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Dabigatran etexilate low
- **DRUG:** Dabigatran etexilate high
- **DRUG:** Moxifloxacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02170987
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2006-05
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02170987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02170987, "Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02170987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*